CervoMed's neflamapimod gets UK Innovation Passport for DLB treatment

CervoMed Inc.

Innovation Passport awarded under UK ILAP for neflamapimod in dementia with Lewy bodies.
Program designed to accelerate time to market and facilitate patient access in the UK.
Provides coordinated guidance from MHRA, NHS, and HTA bodies (NICE, SMC, AWTTC).
DLB is the second most common progressive dementia in older people in the UK; no approved treatment.
CervoMed plans to use ILAP support to prepare for a Phase 3 trial of neflamapimod.

Featured in Daily 8-K Digest

Selected #6 for 2026-08-04. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.